A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors

Next Previous
Trial Profile

A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Genolimzumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors CBT Pharmaceuticals

    • Most Recent Events

    • 30 Mar 2017 According to a CBT Pharmaceuticals media release, the first patient has been enrolled in this trial.
    • 14 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 23 Feb 2017 According to a CBT Pharmaceuticals media release, this study will be initiated in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top